

HOW TO SEND IN PRESCRIPTIONS

Once you make a clinical decision to prescribe GOCOVRI[®] for your patients, prescribing GOCOVRI can be done via **e-prescribe, fax, and/or phone**.
For both new and current GOCOVRI patients, GOCOVRI will be mailed directly to their home.

E-PRESCRIBE

1. Search for **Walgreens Specialty Pharmacy** within your e-prescribing platform.

Walgreens Specialty Pharmacy
PENNSYLVANIA
130 Enterprise Drive
Pittsburgh, PA 15275
NPI: 1972560688

E-scripts should be sent to specialty pharmacy noted in box to the right.

Tip: Some e-prescribing platforms have an option to search for pharmacies by "retail" and "mail order." Look under **"mail order."**

2. Include an office **contact name and phone number** in notes section. Also, include the applicable **ICD-10 Diagnosis Code(s)** listed below.
3. Download the **Prescription Form** on www.GocovriHCP.com. Please send the **Patient Authorization** (page 2) once signed by the patient.

Note: For the **4-week free trial** enrollment, a separate e-script is required. Follow steps 1 and 2, and in the notes section, write: "Enroll Patient in Free Trial Program."

FAX

1. Go to www.GocovriHCP.com.
2. Download and complete the GOCOVRI **Prescription Form** (which includes a **4-week free trial** of GOCOVRI to select for eligible patients).*
3. Ensure **Patient Authorization signature** is included on page 1 of the **Prescription Form** (Option: Send copy of signed Patient Authorization Form found on page 2).
4. Fax to: **1-844-826-7626**.

PHONE

1. Call **1-844-GOCOVRI (1-844-462-6874)**.
2. **Press #1** (identify yourself as a prescriber wanting to prescribe GOCOVRI).
3. Request to speak with a pharmacist to prescribe GOCOVRI. Inform the pharmacist if you'd like to enroll the patient in the **4-week free trial** program.

ICD-10 Diagnosis Code(s)

G20.A2 (Parkinson's disease *without* dyskinesia, with fluctuations)
G20.B1 (Parkinson's disease with dyskinesia, without mention of fluctuations)
G20.B2 (Parkinson's disease with dyskinesia, with fluctuations)

If a patient signature cannot be obtained, a GOCOVRI Onboard[®] team member can help follow up for consent.

*No purchase of GOCOVRI or enrollment into GOCOVRI Onboard[®] is required. Full Terms & Conditions: GocovriHCP.com/terms-and-conditions.

INDICATIONS

GOCOVRI[®] is indicated:

- For the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications
- As adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing "off" episodes

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

- GOCOVRI is contraindicated in patients with end-stage renal disease (creatinine clearance below 15 mL/min/1.73 m²).

Please see additional Important Safety Information on next page and full [Prescribing Information](#).

4-WEEK FREE TRIAL

This program provides new, eligible patients with a 4-week supply of GOCOVRI.
No purchase is required for your patients to participate.*

\$20 CO-PAY

With the GOCOVRI Co-Pay Assistance Program, eligible commercially insured patients pay as little as \$20 per prescription until the maximum benefit is reached.†

**For more information, call GOCOVRI Onboard at
1-844-GOCOVRI (1-844-462-6874) M-F 8 AM-8 PM ET**

IN-OFFICE SAMPLES are available to provide you and your patients with the clinical experience to determine if GOCOVRI is the next right step in their treatment regimen.‡

Contact your local GOCOVRI Sales Representative or Request a Rep at GocovriHCP.com to obtain samples.

*No enrollment into GOCOVRI Onboard is required. Full Terms & Conditions: GocovriHCP.com/terms-and-conditions.

†This offer is valid only for patients who have commercial (non-government-funded) insurance and must meet eligibility requirements. See full Terms & Conditions at GocovriHCP.com/terms-and-conditions.

‡Patients may either participate in the free-trial program or the in-office sample program, but not both.

IMPORTANT SAFETY INFORMATION (CONT'D)

WARNINGS AND PRECAUTIONS

- **Falling Asleep During Activities of Daily Living and Somnolence:** Patients treated with Parkinson's disease medications have reported falling asleep during activities of daily living. If a patient develops daytime sleepiness during activities that require full attention (e.g., driving a motor vehicle, conversations, eating), GOCOVRI should ordinarily be discontinued, or the patient should be advised not to drive and to avoid other potentially dangerous activities.
- **Suicidality and Depression:** Monitor patients for depression, including suicidal ideation or behavior. Prescribers should consider whether the benefits outweigh the risks of treatment with GOCOVRI in patients with a history of suicidality or depression.
- **Hallucinations/Psychotic Behavior:** Patients with a major psychotic disorder should ordinarily not be treated with GOCOVRI because of the risk of exacerbating psychosis. Observe patients for the occurrence of hallucinations throughout treatment, especially at initiation and after dose increases.
- **Dizziness and Orthostatic Hypotension:** Monitor patients for dizziness and orthostatic hypotension, especially after starting GOCOVRI or increasing the dose. Concomitant use of alcohol when using GOCOVRI is not recommended.
- **Withdrawal-Emergent Hyperpyrexia and Confusion:** Rapid dose reduction or abrupt discontinuation of GOCOVRI may cause an increase in the symptoms of Parkinson's disease or cause delirium, agitation, delusions, hallucinations, paranoid reaction, stupor, anxiety, depression, or slurred speech. Avoid sudden discontinuation of GOCOVRI.
- **Corneal Edema:** Has been reported and onset can occur within a few weeks to several years. Symptoms include sudden onset blurry vision, or progressive vision loss, with or without eye pain. Corneal involvement is usually bilateral. Corneal grafts have been required when not recognized. Permanent damage can occur if amantadine is continued. Ask patients if their vision has changed and obtain ophthalmologic exams to rule out corneal edema if changes occur. If corneal edema occurs, taper and discontinue GOCOVRI. Resolution typically begins within weeks of cessation.
- **Impulse Control/Compulsive Behaviors:** Patients can experience intense urges (e.g., gambling, sexual, money spending, binge eating) and the inability to control them. It is important for prescribers to ask patients or their caregivers about the development of new or increased urges. Consider dose reduction or stopping GOCOVRI.

ADVERSE REACTIONS

- The most common adverse reactions (>10% and greater than placebo) were hallucination, dizziness, dry mouth, peripheral edema, constipation, falls, and orthostatic hypotension.

Please see full [Prescribing Information](#).



GOCOVRI is a registered trademark of Adamas Pharma, LLC, a subsidiary of Supernus Pharmaceuticals, Inc. All other trademarks are property of their respective owners.
© 2025 Supernus Pharmaceuticals, Inc. All rights reserved. GOC-2022-0965 V4.